首页> 外文期刊>Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz >Reliable health information for patients with rare diseases. Quality demands defined by the National Action Plan and how they are put into practice
【24h】

Reliable health information for patients with rare diseases. Quality demands defined by the National Action Plan and how they are put into practice

机译:罕见疾病患者的可靠健康信息。 国家行动计划定义的质量要求以及它们如何实践

获取原文
获取原文并翻译 | 示例
           

摘要

Information for patients with rare diseases has to adhere to strict quality criteria in order to support individual treatment decisions or coping strategies. However, developers are facing specific challenges: For example, the evidence is often insufficient or of very low quality. In the context of the National Action League for People with Rare Diseases (NAMSE), criteria have been developed that assure high-quality information on rare diseases. Core criteria comprise the involvement of patients or their advocates in all stages of the development process, the systematic search and assessment of the evidence, systematic collection of patient experience, transparency in terms of people involved and funding, and nondirective and neutral formulation of content and documentation of the process. In a joint project between the Alliance for Chronic Rare Diseases (ACHSE e. V.) and the German Agency for Quality in Medicine (A"ZQ), ten short information leaflets on different rare diseases have been developed in the past three years, conceived to show the applicability of these criteria. First experiences with this format show that the criteria are adaptive to a broad range of diverse rare diseases and settings. Involving patients and their advocates throughout the whole development process - from prioritization to development of methods and provision of patient experience and coping strategies - is crucial. Insufficient evidence remains a challenge. The examples show that in the absence of proven findings, information that matters to patients and reflects this uncertainty is feasible.
机译:含有罕见疾病的患者的信息必须遵守严格的质量标准,以支持个人治疗决策或应对策略。然而,开发人员面临特定的挑战:例如,证据通常不足或质量非常低。在国家行动联盟的稀有疾病(纳斯)的联盟的背景下,已经制定了标准,以确保稀有疾病的高质量信息。核心标准包括患者或其倡导者在开发过程中的所有阶段的参与,系统检索和评估证据,系统地收集患者体验,涉及的人们的透明度和资金的透明度,以及内容的非指导性和中立的制定流程的文档。在慢性罕见疾病联盟(ACHSE e。)和德国药物质量(“ZQ)的联盟之间的联合项目中(A”ZQ),过去三年已经开发了十种短信息传单,构思了展示这些标准的适用性。第一次具有这种格式的经验表明,该标准适应广泛的各种罕见疾病和环境。涉及患者以及整个开发过程中的倡导者 - 从优先顺序到发展方法和提供患者经验和应对策略 - 至关重要。证据不足仍然是一个挑战。这些例子表明,在没有经过验证的调查结果,对患者来说重要的信息并反映这种不确定性是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号